ABT-263 (Navitoclax)Catalog No. A10022

Quick Overview

ABT-263 also called Navitoclax is a potent and orally bioavailable Bcl-2 family inhibitor (Ki's of <1 nmol/L for Bcl-2, Bcl-xL, and Bcl-w).ABT-263 maintains a high affinity for Bcl-xL, Bcl-2, and Bcl-w, (Ki ≤1 nmol/L), but binds more weakly to Mcl-1 and A1.[1]

Products are for laboratory research use only. Not for human use. We do not sell to patients.

ABT-263 (Navitoclax)

ABT-263 (Navitoclax)  Citations(10)
  • Momeny M, .et al. The ERBB receptor inhibitor dacomitinib suppresses proliferation and invasion of pancreatic ductal adenocarcinoma cells, Cell Oncol (Dordr), 2019, Apr 25 PMID: 31025257
  • Anderson R, .et al. Length-independent telomere damage drives postmitotic cardiomyocyte senescence, EMBO J, 2019, Feb 8. pii: e100492 PMID: 30737259
  • Shinya Ishida, .et al. Mechanisms for mTORC1 activation and synergistic induction of apoptosis by ruxolitinib and BH3 mimetics or autophagy inhibitors in JAK2-V617F-expressing leukemic cells including newly established PVTL-2, Oncotarget, 2018, Jun 1; 9(42): 26834-26851 PMID: 29928488
  • Rhys Anderson, .et al. Length-independent telomere damage drives cardiomyocyte senescence, bioRxiv, 2018, 2018
  • Ryuta Mikawa, .et al. Elimination of p19ARF-expressing cells protects against pulmonary emphysema in mice, Aging Cell, 2018, Oct; 17(5): e12827 PMID: 30058137
  • Joo Sang Lee, .et al. Harnessing synthetic lethality to predict the response to cancer treatment, Nat Commun, 2018, 9: 2546 PMID: 29959327
  • Toshiyuki Sumi, .et al. Survivin knockdown induces senescence in TTF-1-expressing, KRAS-mutant lung adenocarcinomas, Int J Oncol, 2018, Jul; 53(1): 33-46 PMID: 29658609
  • Wei TW, .et al. Aurora A and NF-κB Survival Pathway Drive Chemoresistance in Acute Myeloid Leukemia via the TRAF-Interacting Protein TIFA, Cancer Res, 2017, Jan 15;77(2):494-508 PMID: 28069801
  • Yusuke Takagi, .et al. SPIB is a novel prognostic factor in diffuse large B-cell lymphoma that mediates apoptosis via the PI3K-AKT pathway, Cancer Sci, 2016, Sep; 107(9): 1270-1280 PMID: 27348272
  • Matsumoto M, .et al. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells, Biochem Biophys Res Commun, 2016, Apr 29;473(2):490-6 PMID: 26996126
  • Product Information
    Catalog Num A10022
    M. Wt 974.6
    Formula C47H55ClF3N5O6S3
    Solubility DMSO
    Purity >98%
    Storage at -20°C 3 years Powder
    CAS No. 923564-51-6
    Synonyms ABT263
    SMILES Code CC1(CCC(=C(C1)CN2CCN(CC2)C3=CC=C(C=C3)C(=O)NS(=O)(=O)C4=CC(=C(C=C4)N[[email protected]](CCN5CCOCC5)CSC6=CC=CC=C6)S(=O)(=O)C(F)(F)F)C7=CC=C(C=C7)Cl)C

    Biological activity
    Introduction

    ABT-263 also called Navitoclax is a potent and orally bioavailable Bcl-2 family inhibitor (Ki's of <1 nmol/L for Bcl-2, Bcl-xL, and Bcl-w).ABT-263 maintains a high affinity for Bcl-xL, Bcl-2, and Bcl-w, (Ki ≤1 nmol/L), but binds more weakly to Mcl-1 and A1.[1]

    Targets
    Bcl-xL (Cell-free assay) Bcl-2 (Cell-free assay) Bcl-w (Cell-free assay) A1 (Cell-free assay) Mcl-1 (Cell-free assay)
    <=0.5 nM(Ki)<=1 nM(Ki)<=1 nM(Ki)354 nM(Ki)550 nM(Ki)
    Solubility
    Solubility (25C)* In vitro DMSO 100 mg/mL (102.6 mM)
    Water <1 mg/mL (<1 mM)
    Ethanol <1 mg/mL (<1 mM)
    * <1 mg/ml means slightly soluble or insoluble.
    * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
    Reference
    • Tse C, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008 May 1;68(9):3421-8. doi: 10.1158/0008-5472.CAN-07-5836.
    • Chen J, et al. The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Mol Cancer Ther. 2011 Dec;10(12):2340-9. doi: 10.1158/1535-7163.MCT-11-0415. Epub 2011 Sep 13.
    • Shoemaker AR, et al. (2008) Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin Cancer Res 14(11):3268–3277.
    • Santi Suryani, et al. Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts. Clin Cancer Res. 2014 Sep 1;20(17):4520-31. doi: 10.1158/1078-0432.CCR-14-0259. Epub 2014 Jul 10.
    Return Policy Contact information
    Adooq Bioscience has Satisfaction Guarantee return policy. You may return/exchange any items within 365 days from the original purchase date if you are not satisfied with your purchase, either for protocol related or product related problems.

    >>This offer is only valid for products purchased directly from Adooq and its authorized distributors.

    >>Prior to returning any items, please contact the Customer Service ([email protected]) to obtain an Return/Exchange Authorization. Items returned without prior authorization may not be accepted. Any items returned to Adooq should be in the original packaging and in the same condition as originally purchased.


    Website: www.adooq.com
    Order: [email protected]
    Phone:
    (866)930-6790 (US & Canada)
    +1-323-389-9269 (Outside of US & CAN)
    Fax:
    (866)333-9607 (US & Canada)
    +1-323-606-8156 (Outside of US & CAN)
    Support:
    [email protected]

    High Purity Kinase Inhibitors on Signaling Pathways

    Copyright© 2006-2017 Adooq BioScience LLC, All Rights Reserved.
    4000 Barranca Parkway, Suite 250, Irvine, CA 92604 USA. Tel: 855-930-6790